

## Drug Status Report

**Drug:** HU-211


**Drug Name Status:** HU-211 is the common name.

**Other Names:** Dexanabinol;  
(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo  
[c]chromen-1-ol; (+)-11-OH- $\Delta$ 8-THC-DMH


**Chemical Name:**

(6aS-trans)-3-(1,1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-  
6H-dibenzo(b,d)pyran-9-methanol


**Chemical structure:**




HU-211



$\Delta$ 9-THC



$\Delta$ 8-THC



Nabilone

**Molecular Formula:** C<sub>25</sub>H<sub>38</sub>O<sub>3</sub>

**Pharmacological class / Application:** cannabinoid receptor agonist

**International status:**

US: The substance is not listed on the schedules to the US Controlled Substances Act. HU-210 is not controlled<sup>1</sup> in the US.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control nor the Green List - List of Psychotropic Substances under International Control.

---

<sup>1</sup> [http://www.deadiversion.usdoj.gov/drugs\\_concern/spice/spice\\_hu211.htm](http://www.deadiversion.usdoj.gov/drugs_concern/spice/spice_hu211.htm)

Canadian Status: Item 1 of Schedule II to the CDSA is, “Cannabis, its preparations, derivatives and similar synthetic preparations including:”. Six chemical substances are listed under this heading: cannabidiol; cannabitol; nabilone; pyrahexyl; tetrahydrocannabinol; and DMPH. The chemical structures of HU-211,  $\Delta^9$ -THC,  $\Delta^8$ -THC and nabilone are shown above. HU-210 is a synthetic substance that is structurally similar to other cannabinoids listed in Schedule II to the CDSA. HU-211 is also a cannabinoid receptor agonist<sup>2</sup>.

Based on the similarity of its structure to the cannabinoids listed on Schedule II to the CDSA, HU-211 should be considered to be included in Schedule II to the Act.

Recommendation: HU-211 is included in item 1 of Schedule II to the CDSA and is a controlled substance.

July 16, 2009

---

<sup>2</sup> Rodríguez de Fonseca F, Rubio P, Menzaghi F, Merlo-Pich E, Rivier J, Koob GF, Navarro M., *Pharmacol Exp Ther.* 1996 Jan;276(1):56-64.